Nephrolithiasis in Cushing's disease: Prevalence, etiopathogenesis, and modification after disease cure

被引:69
作者
Faggiano, A
Pivonello, R
Melis, D
Filippella, M
Di Somma, C
Petretta, M
Lombardi, G
Colao, A
机构
[1] Univ Naples Federico II, Dept Mol & Clin Endocrinol & Oncol, I-80131 Naples, Italy
[2] Univ Naples Federico II, Dept Pediat, I-80131 Naples, Italy
[3] Univ Naples Federico II, Dept Internal Med, I-80131 Naples, Italy
关键词
D O I
10.1210/jc.2002-021494
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The pathogenesis of nephrolithiasis in Cushing's syndrome is still not completely clarified. The current study aimed at investigating prevalence of nephrolithiasis and role of different lithogenic factors in Cushing's disease ( CD). Forty-six CD patients ( 24 with active and 22 with cured disease) and 46 sex- and age-matched controls entered the study. Body mass index, blood pressure, fasting glucose and insulin, serum and urinary creatinine, urea, uric acid, electrolytes, and cystine, urinary volume, pH, oxalate, and citrate levels, and renal ultrasonography ( US) were performed in all patients and controls. Nephrolithiasis was found in 50% of active patients, 27.3% of cured patients, and 6.5% of controls ( P < 0.001). Compared with controls, patients with active disease had a significantly increased prevalence of obesity, arterial hypertension, diabetes mellitus, hypercalciuria, hypocitraturia, and hyperuricosuria, significantly higher levels of serum and urinary cystine, urinary creatinine, urea, uric acid, potassium, calcium, phosphorus, and oxalate, significantly lower levels of urinary citrate levels. Compared with controls, patients cured from CD had a significantly increased prevalence of obesity, systemic arterial hypertension, and diabetes mellitus, whereas urinary citrate was significantly decreased. At multivariate analysis, a significantly increased risk to develop kidney stones was independently associated with urinary excretion of uric acid ( odds ratio = 1.6, confidence interval = 1.0-2.5) and systemic arterial blood pressure ( odds ratio = 2.6, confidence interval = 1.1 - 6.6). In conclusion, patients with active CD have an increased prevalence of nephrolithiasis compared with general population, which decreases but not disappears in patients successfully cured from the disease. This complication is likely caused by the synergic effect of different hypercortisolism-dependent metabolic and hemodynamic abnormalities, among which systemic arterial hypertension and excessive urinary uric acid excretion seem to play a pivotal role.
引用
收藏
页码:2076 / 2080
页数:5
相关论文
共 27 条
[1]   EFFECT OF CORTISOL ON GROWTH AND URIC ACID EXCRETION IN CHICK [J].
ADAMS, BM .
JOURNAL OF ENDOCRINOLOGY, 1968, 40 (02) :145-&
[2]   CLINICAL APPRAISAL OF CREATININE CLEARANCE AS A MEASUREMENT OF GLOMERULAR-FILTRATION RATE [J].
BAUER, JH ;
BROOKS, CS ;
BURCH, RN .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1982, 2 (03) :337-346
[3]  
Borch-Johnsen K, 1999, LANCET, V354, P617
[4]   Essential arterial hypertension and stone disease [J].
Borghi, L ;
Meschi, T ;
Guerra, A ;
Briganti, A ;
Schianchi, T ;
Allegri, F ;
Novarini, A .
KIDNEY INTERNATIONAL, 1999, 55 (06) :2397-2406
[5]   Mechanisms of glucocorticoid action in bone: Implications to glucocorticoid-induced osteoporosis [J].
Canalis, E .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (10) :3441-3447
[6]   URIC-ACID AND CALCIUM-OXALATE NEPHROLITHIASIS [J].
COE, FL ;
KASSIRER, JP ;
SHIELDS, M ;
COHEN, JJ ;
BUSHINSKY, D ;
ZITMAN, I ;
SOBEL, G ;
MICHEL, S ;
LANGMAN, C .
KIDNEY INTERNATIONAL, 1983, 24 (03) :392-403
[7]   Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure [J].
Colao, A ;
Pivonello, R ;
Spiezia, S ;
Faggiano, A ;
Ferone, D ;
Filippella, M ;
Marzullo, P ;
Cerbone, G ;
Siciliani, M ;
Lombardi, G .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (08) :2664-2672
[8]   Twenty-four-hour urine chemistries and the risk of kidney stones among women and men [J].
Curhan, GC ;
Willett, WC ;
Speizer, FE ;
Stampfer, MJ .
KIDNEY INTERNATIONAL, 2001, 59 (06) :2290-2298
[9]  
Cushing H, 1932, B JOHNS HOPKINS HOSP, V50, P137
[10]   Effectiveness of chronic treatment with alendronate in the osteoporosis of Cushing's disease [J].
Di Somma, C ;
Colao, A ;
Pivonello, R ;
Klain, M ;
Faggiano, A ;
Tripodi, FS ;
Merola, B ;
Salvatore, M ;
Lombardi, G .
CLINICAL ENDOCRINOLOGY, 1998, 48 (05) :655-662